15 MAY 2018
SAB Biotherapeutics expands VAC team
Growing bioscience company promotes Bobbitt and hires Harris
Sioux Falls, S.D. – SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical development company, has expanded its Vaccinology and Antibody Characterization (VAC) team with the promotion of Molly Bobbitt to VAC Manager and hiring of Seth Harris as Research Associate.
SAB’s proprietary DiversitAb™ platform enables the rapid production of large amounts of targeted human polyclonal antibodies to be used as immunotherapies for the treatment of inflammation, cancer, autoimmune disorders and emerging infectious diseases.
The first-of-its-kind platform leverages transchromosomic bovine (Tc Bovine™) that produce human antibodies (rather than bovine) in response to vaccination with a disease antigen.
The VAC department works with the Tc Bovine both evaluating and maximizing the production of human antibodies to meet production criteria and levels. They also formulate the vaccines for the cattle from disease antigens and create the protocol for optimal production of human antibodies and health of the animals. In addition, the team analyzes the samples from pre-clinical studies and human clinical trials and generates data.
The expansion of the VAC team will accommodate a larger number of production animals, disease targets and clinical trials pacing with the company’s growth.
Molly Bobbitt is a 10-year veteran of the Tc Bovine and platform dating back to August of 2006. She has worked as Research Associate and later Senior Research Associate in the VAC through the evolution of the technology.
“I like the work because it’s intellectually stimulating,” said Bobbitt. “While I’ve been in the lab and essentially done ELISAs for 11 years–there’s always new projects and advancements. Essentially, I want to help people and am excited about what we can accomplish helping millions of people around the world by figuring out some of the toughest challenges.”
As VAC Manager, Molly will oversee the laboratory; lead the vaccine production for the Tc Bovine and bioanalytic assay development for the resulting human antibody therapeutic evaluation.
“With the company’s continued growth we needed more depth in our department,” said Hua Wu, PhD, SAB Biotherapeutics senior vice president of vaccine and antibody development. “We’ve been able to develop and formulate our vaccines specifically for the Tc Bovine to produce large volumes of highly-potent therapeutic human antibodies. Molly has been instrumental in this progress.
Molly holds a Bachelor of Science in Biochemistry from the University of Nebraska-Lincoln where she worked as a teaching assistant and undergraduate researcher. A 2001 graduate Roosevelt High School, Molly resides in Sioux Falls with her husband David and daughter Aurora.
Seth Harris has been hired as research associate after spending the last five years with Elanco Animal Health as QC Lab Technician / Environmental Monitor and most recently Bacterin Technician where he produced antigens for use in livestock vaccine production.
“I’m excited to be working with the team and the science at SAB” said Harris. “It’s among some of the most advanced antibody science in the world; and the people really care about the work–and each other. We all want to make a difference.”
Seth is returning to a team and technology he knows well having worked as a research associate for Sanford Applied Biosciences and intern for Hematech, SAB’s predecessors. He also worked as an undergraduate researcher while attending South Dakota State University where he received his Bachelor of Science in Microbiology in 2011. Seth is a 2007 graduate of Lincoln High School and resides with his wife Jessica in Sioux Falls with whom he enjoys traveling.
“Seth is a great addition to our team,” said Wu. “He brings a good general knowledge of the platform, the science and techniques as well as broad experience from the production side which will be valuable as we continue to scale.”
The VAC team recently developed influenza and MERS-CoV vaccines for the Tc Bovine to produce human antibody immunotherapies for the company’s Phase 2 clinical trials.
With the addition of Harris, SAB Biotherapeutics has 25 employees between its corporate headquarters, currently housed within the Sanford Research Center, and biopharmaceutical production pharm in its second phase of construction near Canton.
# # #